AMWatch

Novo Ventures investerer millioner i konkurrent til Bavarian Nordic

Det London-baserede biotekselskab Reviral har rejst 351 mio. kr. til den fortsatte udvikling af dets fase 2-kandidat mod luftvejssygdommen RSV. Blandt investorerne er Novo Ventures.

Photo: Novo Holdings/PR

Konkurrencen på det mulige milliardmarked for behandling af luftvejssygdommen RSV spidser til, og nu bidrager også Novo Holdings til at sætte yderligere fart i feltet.

Således har Novo Ventures investeret et uoplyst beløb i britiske Reviral, der netop har gennemført en serie b-finansieringsrunde, der har indbragt biotekselskabet samlet 55 mio. amerikanske dollars, svarende til knap 351 mio. kr.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Norway has the fastest growing investment fund market in Europe

So far in 2021, Norway has experienced massive inflows to its investment fund markets, beating former records. The pandemic and different government initiatives have resulted in an increased savings rate. Data also show that market shares are shifting among Norwegian fund managers.

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch